表紙
市場調査レポート

好中球減少症:パイプライン製品の分析

Neutropenia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192734
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
好中球減少症:パイプライン製品の分析 Neutropenia - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 77 Pages
概要

好中球減少症は、白血球の一種で、感染症を撃退する役目の好中球の数が異常に少ない状態を指します。兆候と症状は、発熱、頻繁な感染、口内炎、歯肉感染症、排尿障害などが見られます。

当レポートでは、好中球減少症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

好中球減少症の概要

治療薬の開発

  • パイプライン製品の概要

好中球減少症:企業で開発中の治療薬

好中球減少症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

好中球減少症:企業で開発中の製品

好中球減少症の治療薬開発に従事している企業

  • Apotex Inc.
  • Biogenomics Limited
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Limited
  • Ligand Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Prolong Pharmaceuticals, LLC
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International, LLC
  • 東光薬品工業
  • USV Limited

好中球減少症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

好中球減少症:最近のパイプライン動向

好中球減少症:休止中のプロジェクト

好中球減少症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7850IDB

Summary

Global Markets Direct's, 'Neutropenia - Pipeline Review, H1 2016', provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neutropenia
  • The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects
  • The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neutropenia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neutropenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neutropenia Overview
  • Therapeutics Development
    • Pipeline Products for Neutropenia - Overview
  • Neutropenia - Therapeutics under Development by Companies
  • Neutropenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Neutropenia - Products under Development by Companies
  • Neutropenia - Companies Involved in Therapeutics Development
    • Apotex Inc.
    • Biogenomics Limited
    • Cellerant Therapeutics, Inc.
    • Coherus BioSciences, Inc.
    • Dr. Reddy's Laboratories Limited
    • Ligand Pharmaceuticals, Inc.
    • NAL Pharmaceuticals Ltd.
    • Prolong Pharmaceuticals, LLC
    • Richter Gedeon Nyrt.
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
    • Toko Pharmaceutical Industries Co., Ltd.
    • USV Limited
  • Neutropenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACN-8337 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LG-7455 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • romyelocel-L - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-7 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tamibarotene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neutropenia - Recent Pipeline Updates
  • Neutropenia - Dormant Projects
  • Neutropenia - Product Development Milestones
    • Featured News & Press Releases
      • Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
      • Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
      • Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
      • Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
      • Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim
      • Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
      • Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
      • Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study
      • Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
      • Dec 17, 2014: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neutropenia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Neutropenia - Pipeline by Apotex Inc., H1 2016
  • Neutropenia - Pipeline by Biogenomics Limited, H1 2016
  • Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016
  • Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H1 2016
  • Neutropenia - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016
  • Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2016
  • Neutropenia - Pipeline by Sandoz International GmbH, H1 2016
  • Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H1 2016
  • Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016
  • Neutropenia - Pipeline by USV Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Neutropenia Therapeutics - Recent Pipeline Updates, H1 2016
  • Neutropenia - Dormant Projects, H1 2016
  • Neutropenia - Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Neutropenia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top